Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q2 EPS of $0.78, $0.05 better than the analyst estimate of $0.73. Revenue for the quarter came in at $125.3 million versus the consensus estimate of $122.7 million.

GUIDANCE:

Fulgent Genetics, Inc. sees Q3 2022 revenue of $105 million, versus the consensus of $106.3 million.

Fulgent Genetics, Inc. sees FY2022 EPS of $6.00, versus the consensus of $6.23. Fulgent Genetics, Inc. sees FY2022 revenue of $665 million, versus the consensus of $649.6 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.